Clinuvel Pharmaceuticals Ltd (AU:CUV) — Market Cap & Net Worth

$328.56 Million USD · AU$464.36 Million AUD · Rank #14593

Market Cap & Net Worth: Clinuvel Pharmaceuticals Ltd (CUV)

Clinuvel Pharmaceuticals Ltd (AU:CUV) has a market capitalization of $328.56 Million (AU$464.36 Million) as of May 6, 2026. Listed on the AU stock exchange, this Australia-based company holds position #14593 globally and #385 in its home market, demonstrating a 2.32% increase in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clinuvel Pharmaceuticals Ltd's stock price AU$9.25 by its total outstanding shares 50200740 (50.20 Million). Analyse how efficiently does Clinuvel Pharmaceuticals Ltd generate cash to see how efficiently the company converts income to cash.

Clinuvel Pharmaceuticals Ltd Market Cap History: 2015 to 2026

Clinuvel Pharmaceuticals Ltd's market capitalization history from 2015 to 2026. Data shows growth from $92.30 Million to $328.56 Million (12.24% CAGR).

Index Memberships

Clinuvel Pharmaceuticals Ltd is a constituent of 5 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
Australia All Ordinaries AORD	$1.96 Trillion	0.02%	#259 of 495
S&P/ASX 200 AXJO	$1.84 Trillion	0.02%	#157 of 200
S&P/ASX 200 Accumulated AXJOA	$1.84 Trillion	0.02%	#157 of 200
S&P/ASX 300 AXKO	$2.12 Trillion	0.02%	#241 of 300
ASX Small Ordinaries AXSO	$294.63 Billion	0.11%	#149 of 200

Weight: Clinuvel Pharmaceuticals Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Clinuvel Pharmaceuticals Ltd Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Clinuvel Pharmaceuticals Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

4.66x

Clinuvel Pharmaceuticals Ltd's market cap is 4.66 times its annual revenue

Industry average: 3784.60x Lower than industry average

Latest Price to Earnings (P/E) Ratio

12.24x

Clinuvel Pharmaceuticals Ltd's market cap is 12.24 times its annual earnings

Industry average: 0.17x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$261.46 Million	$6.82 Million	-$3.12 Million	38.34x	N/A
2017	$287.43 Million	$16.77 Million	$7.18 Million	17.14x	40.03x
2018	$635.92 Million	$25.49 Million	$13.22 Million	24.95x	48.09x
2019	$1.00 Billion	$31.05 Million	$18.13 Million	32.22x	55.17x
2020	$785.88 Million	$32.57 Million	$16.65 Million	24.13x	47.21x
2021	$958.72 Million	$47.98 Million	$24.73 Million	19.98x	38.77x
2022	$765.08 Million	$65.72 Million	$20.88 Million	11.64x	36.64x
2023	$566.45 Million	$78.32 Million	$30.60 Million	7.23x	18.51x
2024	$428.37 Million	$88.18 Million	$35.64 Million	4.86x	12.02x
2025	$442.58 Million	$95.02 Million	$36.17 Million	4.66x	12.24x

Competitor Companies of CUV by Market Capitalization

Companies near Clinuvel Pharmaceuticals Ltd in the global market cap rankings as of May 6, 2026.

Key companies related to Clinuvel Pharmaceuticals Ltd by market ranking:

Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#221	Vertex Pharmaceuticals Inc	NASDAQ:VRTX	$109.06 Billion	$429.85
#357	Regeneron Pharmaceuticals Inc	NASDAQ:REGN	$73.69 Billion	$709.21
#519	UCB SA	BR:UCB	$50.85 Billion	€228.50
#567	argenx NV ADR	NASDAQ:ARGX	$45.97 Billion	$787.95

Clinuvel Pharmaceuticals Ltd Historical Marketcap From 2015 to 2026

Between 2015 and today, Clinuvel Pharmaceuticals Ltd's market cap moved from $92.30 Million to $ 328.56 Million, with a yearly change of 12.24%.

Year	Market Cap	Change (%)
2026	AU$328.56 Million	-25.76%
2025	AU$442.58 Million	+3.32%
2024	AU$428.37 Million	-24.38%
2023	AU$566.45 Million	-25.96%
2022	AU$765.08 Million	-20.20%
2021	AU$958.72 Million	+21.99%
2020	AU$785.88 Million	-21.45%
2019	AU$1.00 Billion	+57.33%
2018	AU$635.92 Million	+121.24%
2017	AU$287.43 Million	+9.93%
2016	AU$261.46 Million	+183.26%
2015	AU$92.30 Million	--

End of Day Market Cap According to Different Sources

On May 5th, 2026 the market cap of Clinuvel Pharmaceuticals Ltd was reported to be:

Source	Market Cap
Yahoo Finance	$328.56 Million USD
MoneyControl	$328.56 Million USD
MarketWatch	$328.56 Million USD
marketcap.company	$328.56 Million USD
Reuters	$328.56 Million USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Clinuvel Pharmaceuticals Ltd

AU:CUV Australia Biotechnology

Market Cap

$328.56 Million

AU$464.36 Million AUD

Market Cap Rank

#14593 Global

#385 in Australia

Share Price

AU$9.25

Change (1 day)

+0.87%

52-Week Range

AU$8.79 - AU$13.70

All Time High

AU$44.55